MedTrace Logo

Gait Rehabilitation Following an Anterior Cruciate Ligament Reconstruction

NCT02930239 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-10-12

No results posted yet for this study

Summary

A randomized control trial where subjects following an anterior cruciate ligament reconstruction will be randomized to either a control group who will receive the normal rehabilitation or an experimental group who will perform a 2-week gait rehabilitation using the anti-gravity treadmill in addition to the normal rehabilitation. The intervention will be added to the existing care received at Linkoping University Hospital 2 weeks post-surgery, while the evaluation will be performed in week 5 and 12 post-surgery using: a 3D-gait analysis (with the Qualisys software), self-reported function questionnaires and a clinical examination.

Conditions

  • Complete Tear, Knee, Anterior Cruciate Ligament

Interventions

OTHER

Gait rehabilitating with reduced bodyweight

Patients will perform 8 sessions of gait rehabilitation with reduced bodyweight using the anti gravity treadmill during week 2-5 post-surgery.

OTHER

Standardized rehabilitation following an anterior cruciate ligament reconstruction at Linkoping University Hospital

Exercises for increased movement and circulation performed on a daily basis.

Sponsors & Collaborators

  • Linkoeping University

    lead OTHER_GOV

Principal Investigators

  • Joanna Kvist, Professor · Linkoeping University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2017-07-31
Completion
2018-02-28

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02930239 on ClinicalTrials.gov